The Medicines (NASDAQ:MDCO) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.

Other research analysts have also recently issued reports about the company. BidaskClub cut The Medicines from a “hold” rating to a “sell” rating in a research note on Saturday, September 8th. Oppenheimer set a $50.00 target price on The Medicines and gave the company a “buy” rating in a research note on Thursday, August 16th. Zacks Investment Research raised The Medicines from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Tuesday, August 7th. B. Riley started coverage on The Medicines in a research note on Thursday, June 7th. They issued a “buy” rating and a $55.00 target price for the company. Finally, Citigroup boosted their target price on The Medicines from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, August 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The Medicines currently has a consensus rating of “Buy” and a consensus target price of $52.63.

Shares of The Medicines stock traded down $0.92 during trading on Monday, reaching $32.83. 557,500 shares of the company were exchanged, compared to its average volume of 1,016,569. The company has a quick ratio of 2.55, a current ratio of 2.60 and a debt-to-equity ratio of 31.23. The Medicines has a twelve month low of $24.45 and a twelve month high of $41.57. The stock has a market cap of $2.49 billion, a PE ratio of -3.91 and a beta of 0.77.

The Medicines (NASDAQ:MDCO) last announced its quarterly earnings data on Wednesday, August 1st. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. The Medicines had a negative return on equity of 394.33% and a negative net margin of 668.93%. The business had revenue of $1.67 million during the quarter, compared to analysts’ expectations of $7.20 million. During the same period in the previous year, the firm earned ($0.72) earnings per share. The firm’s quarterly revenue was down 84.6% compared to the same quarter last year. analysts expect that The Medicines will post -2.52 EPS for the current fiscal year.

In other The Medicines news, CEO Clive Meanwell sold 50,000 shares of the business’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $39.31, for a total value of $1,965,500.00. Following the completion of the transaction, the chief executive officer now directly owns 352,409 shares of the company’s stock, valued at $13,853,197.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders sold 150,000 shares of company stock valued at $5,731,000. Insiders own 10.29% of the company’s stock.

A number of large investors have recently bought and sold shares of MDCO. PointState Capital LP lifted its holdings in shares of The Medicines by 81.5% in the first quarter. PointState Capital LP now owns 3,706,147 shares of the company’s stock valued at $122,080,000 after purchasing an additional 1,663,694 shares in the last quarter. venBio Select Advisor LLC lifted its holdings in shares of The Medicines by 26.2% in the first quarter. venBio Select Advisor LLC now owns 1,635,817 shares of the company’s stock valued at $53,884,000 after purchasing an additional 339,257 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of The Medicines by 797.0% in the second quarter. Advisors Asset Management Inc. now owns 211,686 shares of the company’s stock valued at $790,000 after purchasing an additional 188,086 shares in the last quarter. Antipodean Advisors LLC lifted its holdings in shares of The Medicines by 142.3% in the first quarter. Antipodean Advisors LLC now owns 237,500 shares of the company’s stock valued at $7,823,000 after purchasing an additional 139,500 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its holdings in shares of The Medicines by 4.3% in the first quarter. Westfield Capital Management Co. LP now owns 3,029,611 shares of the company’s stock valued at $99,795,000 after purchasing an additional 125,136 shares in the last quarter.

About The Medicines

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

Featured Article: Are analyst ratings accurate?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.